Ahmad, Firdayani, Irma Ratna Kartika
The fatty liver disease known as steatohepatitis is characterized by liver inflammation. De novo lipogenesis and mevalonate pathway have been identified as contributing to the development of fatty liver. Rheum genus has pharmacological properties such as antioxidant, anti-inflammatory, hepatoprotective, and hypolipidemic. Consequently, the current study investigated bioactive compounds from Rheum genus using in-silico method. The 109 compounds and their natural inhibitors against the enzyme targets ATP-citrate lyase (ACLY), Acetyl-CoA carboxylase (ACC), Fatty Acid Synthase (FASN), Stearoyl-CoA desaturase (SCD1), and HMG-CoA reductase (HMGCR) were performed. The results obtained are in the form of a re-rank score, with the best compound results for each enzyme is Catechin 7,3’-di-O-β-D-glucopyranoside (A1) (-148.73), 4’ - Methoxy - 3, 3’,5 - trihydroxystilbene’ - O - β – D (2"-O-p-coumaryl) - glucopyranoside (A2) (-136,808), 2-Cinnamoyl-1,6-digalloyl glucose (A3) (-149,589), 3-O-Galloyl Epicatechin (A4) (-160,018), and 6-C-Glucopyranosyl Procyanidin B2 (A5) (-84,843) as ACLY, ACC, FASN, SCD1 and HMGCR inhibitors, respectively. Analyses using the ADMET and Lipinski rules revealed that A4 has the potential to be a lead compound for oral drug use, but more research is required. © (2025), (DergiPark). All rights reserved.
Chemistry Study Program, Faculty of Mathematics and Natural Sciences, Jakarta State University (UNJ), Jakarta, Indonesia; Research Center for Vaccine and Drugs, Research Organization for Health, National Research and Innovation Agency (BRIN), South Tangerang, Indonesia
Research at a Glance
Register to unlock
Topics & SDG Alignment
Register to unlock
Collaboration
Register to unlock
Author Profile (Selected)
Register to unlock
References Overview
Register to unlock
Journal & Source
Register to unlock
Metadata & Integrity
Register to unlock